Ketorolac (Systemic) - Drug Information - UpToDate

1/11/22, 6:59 Ketorolac (systemic): Drug information - UpToDate

Official reprint from UpToDate®

www.uptodate.com
© 2022 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Ketorolac (systemic): Drug information
Copyright 1978-2022 Lexicomp, Inc. All rights reserved.
Contributor Disclosures
(For additional information see "Ketorolac (systemic): Patient drug information" and see "Ketorolac (systemic): Pediatric drug information")
For abbreviations, symbols, and age group definitions used in Lexicomp ( show table)
ALERT: US Boxed Warning

Appropriate use:
Ketorolac is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires
analgesia at the opioid level. Oral ketorolac is only indicated as continuation treatment following IV or IM dosing of ketorolac, if
necessary. The total combined duration of use of ketorolac tablets and injection should not exceed 5 days. The recommended total
daily dose of ketorolac tablets (maximum 40 mg) is significantly lower than for ketorolac injection (maximum 120 mg).
Ketorolac is not indicated for use in pediatric patients and is not indicated for minor or chronic painful conditions. Increasing the
dose of ketorolac beyond labeled recommendations will not provide better efficacy but will increase the risk of developing serious
adverse events.
Cardiovascular thrombotic events:
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including
myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
https://www.uptodate.com/contents/ketorolac-systemic-drug-information/print?search=ketorolaco&source=panel_search_result&selectedTitle=1~143&usage_type=panel&showDrugLabel=true&display_rank=1 1/42
Ketorolac is contraindicated in the setting of coronary artery bypass graft surgery.
GI risk:
Ketorolac can cause peptic ulcers, GI bleeding, and/or perforation of the stomach or intestines, which can be fatal. These events can
occur at any time during use and without warning symptoms. Therefore, ketorolac is contraindicated in patients with active peptic
ulcer disease, recent GI bleeding or perforation, and a history of peptic ulcer disease or GI bleeding. Elderly patients and patients
with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
Intrathecal or epidural administration:
Ketorolac is contraindicated for intrathecal or epidural administration due to its alcohol content.
Hypersensitivity:
Hypersensitivity reactions, ranging from bronchospasm to anaphylactic shock, have occurred and appropriate counteractive
measures must be available when administering the first dose of ketorolac injection. Ketorolac is contraindicated in patients with
previously demonstrated hypersensitivity to ketorolac or allergic manifestations to aspirin or other NSAIDs.
Renal risk:
Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume
depletion.
Risk of bleeding:
Ketorolac inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular
bleeding, hemorrhagic diathesis, incomplete hemostasis, and those at high risk of bleeding.
Ketorolac is contraindicated as a prophylactic analgesic before any major surgery.
Risk during labor and delivery:
The use of ketorolac in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibit uterine
contractions.
Concomitant use with nonsteroidal anti-inflammatory drugs:
Ketorolac is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious
NSAID-related adverse events.
Special populations:
Dosage should be adjusted for patients ≥65 years of age, for patients <50 kg (110 lbs) of body weight, and for patients with
moderately elevated serum creatinine. Doses of ketorolac injection are not to exceed 60 mg (total dose per day) in these patients.
Brand Names: US
ReadySharp Ketorolac [DSC]
Brand Names: Canada

ALTI-Ketorolac;
APO-Ketorolac;
JAMP Ketorolac;
Mar-Ketorolac;
MINT-Ketorolac;
Toradol
Pharmacologic Category
Analgesic, Nonopioid;
Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;
Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral
Dosing: Adult
Note: Safety: Use the lowest effective dose for the shortest duration of time; do not shorten dosing interval of 4 to 6 hours.
Contraindications include peptic ulcer disease, history of GI bleed, advanced renal impairment, or risk of renal failure (eg, volume
depletion). Consider administering in combination with a proton pump inhibitor in patients at risk for GI bleeding (eg, taking dual
antiplatelet therapy or an anticoagulant, ≥60 years of age) (Ref). May increase cardiovascular risk (eg, thrombotic events), particularly in
patients with established cardiovascular disease. Patients weighing <50 kg or ≥65 years of age may be at increased risk for adverse
effects; lower doses are recommended. Collapse All
Migraine, severe, acute treatment 
Migraine, severe, acute treatment (off-label use):
Weight ≥50 kg and <65 years of age:
IV: 30 mg once (Ref).
IM: 60 mg once (Ref).
Weight <50 kg or ≥65 years of age:
IV: 15 mg once (Ref).
IM: 30 mg once (Ref).
Pain management 
Pain management, acute:
Note: Do not exceed recommended doses or administer with another nonsteroidal anti-inflammatory drug (NSAID). May
supplement with analgesic(s) from another therapeutic class for breakthrough pain. Oral formulation should not be given as
initial therapy; other better tolerated oral NSAIDs are generally preferred.
Weight ≥50 kg and <65 years of age:
IV: 30 mg as a single dose or 15 to 30 mg every 6 hours as needed; maximum daily dose: 120 mg/day; maximum
duration: 5 days combined (parenteral, oral, and nasal) (Ref).
IM: 30 to 60 mg as a single dose or 15 to 30 mg every 6 hours as needed; alternatively, may administer 10 to 30 mg every
4 to 6 hours as needed; maximum daily dose: 120 mg/day; maximum duration: 5 days combined (parenteral, oral, and
nasal) (Ref).
Oral (only as continuation of IM or IV therapy, not for initial therapy): 20 mg once, followed by 10 mg every 4 to 6
hours as needed; maximum daily dose: 40 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal)
(Ref).
Weight <50 kg or ≥65 years of age:
IV: 15 mg as a single dose or 15 mg every 6 hours as needed; maximum daily dose: 60 mg/day; maximum duration: 5
days combined (parenteral, oral, and nasal) (Ref).
IM: 30 mg as a single dose or 15 mg every 6 hours as needed; alternatively, may administer 10 mg every 4 to 6 hours as
needed; maximum daily dose: 60 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (Ref).
Oral (only as continuation of IM or IV therapy, not for initial therapy): 10 mg every 4 to 6 hours as needed; maximum
daily dose: 40 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or
avoidance. Consult drug interactions database for more information.
Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce
Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Dosage adjustment recommendations:
Note: The risks and benefits of nonsteroidal anti-inflammatory drug (NSAID) therapy in patients with altered kidney function
must be weighed carefully as their use may result in an acute decline in kidney function. Special care should be taken in those
with chronic kidney disease or clinical conditions in which alteration of renal hemodynamics may precipitate acute kidney injury.
Altered kidney function:
eGFR >50 mL/minute/1.73 m2: IM, IV, Oral: No dosage adjustment necessary.
eGFR 10 to 50 mL/minute/1.73 m2:
IM, IV: Some experts recommend to preferably avoid use; if benefits are likely to outweigh risks, consider 7.5 to 15 mg
every 6 hours (Ref); use the lowest effective dose for the shortest duration possible. The manufacturer's labeling states
use is contraindicated in advanced kidney impairment, and Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines recommend avoiding all NSAIDs in patients with eGFR <30 mL/minute/1.73 m2 (Ref).
Oral: 10 mg every 4 to 6 hours as needed; maximum: 40 mg/day; oral dosing is intended to be a continuation of IM or
IV therapy (Ref). The manufacturer's labeling states use is contraindicated in advanced kidney impairment, and KDIGO
eGFR <10 mL/minute/1.73 m2: Some experts recommend avoiding use when possible (Ref). The manufacturer's labeling
states use is contraindicated in advanced kidney impairment, and KDIGO guidelines recommend avoiding all NSAIDs in
patients with eGFR <30 mL/minute/1.73 m2 (Ref).
Hemodialysis, intermittent (thrice weekly): Not dialyzable: IM, IV, Oral: Avoid use; elimination half-life is prolonged, and risk
of GI complications and/or depletion of residual kidney function may be increased with NSAID use (Ref). The manufacturer's
labeling states use is contraindicated in advanced kidney impairment, and KDIGO guidelines recommend avoiding all NSAIDs in
patients with eGFR <30 mL/minute/1.73 m2 (Ref).
Peritoneal dialysis: Unlikely to be significantly dialyzed given very high protein binding (Ref): IM, IV, Oral: Avoid use;
elimination half-life is prolonged, and risk of GI complications and/or depletion of residual kidney function may be increased
with NSAID use (Ref). The manufacturer's labeling states use is contraindicated in advanced kidney impairment, and KDIGO
Dosing: Hepatic Impairment: Adult
There are no dosage adjustments provided in the manufacturer's labeling; use with caution to avoid adverse effects and discontinue if
hepatic function worsens.
Dosing: Pediatric
(For additional information see "Ketorolac (systemic): Pediatric drug information")

Note: To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time. The total
duration of ketorolac (combined IV/IM and oral) should not exceed 5 days (Ref).
Pain management (acute; moderately severe):
Infants and Children <2 years: Limited data available: IV: 0.5 mg/kg/dose every 6 to 8 hours, not to exceed 48 to 72 hours of
treatment; has been used postoperatively primarily following cardiac and abdominal surgery; maximum dose: 15 mg/dose (Ref).
A lower dose of 0.25 mg/kg/dose every 6 to 8 hours has also been recommended (Ref). Note: IM administration has been
described in patients ≥6 months of age (Ref).
Children ≥2 years and Adolescents ≤16 years: Limited data available:
IM, IV: 0.5 mg/kg/dose every 6 to 8 hours; maximum dose: 30 mg/dose, usual reported duration: 48 to 72 hours; not to
exceed 5 days of treatment (Ref).
Oral: 1 mg/kg/dose every 4 to 6 hours; maximum dose: 10 mg/dose; maximum daily dose: 40 mg/day (Ref). Note: Oral
formulation should only be used as continuation of IV or IM therapy; do not use as initial therapy (Ref).
Adolescents ≥17 years: Note: The maximum combined duration of treatment (for parenteral and oral) is 5 days; do not increase
dose or frequency; supplement with low-dose opioids if needed for breakthrough pain.
<50 kg:
IM: 30 mg as a single dose or 15 mg every 6 hours; maximum daily dose: 60 mg/day.
IV: 15 mg as a single dose or 15 mg every 6 hours; maximum daily dose: 60 mg/day.

Oral: Initial: 10 mg, then 10 mg every 4 to 6 hours; maximum daily dose: 40 mg/day.
≥50 kg:
IM: 60 mg as a single dose or 30 mg every 6 hours; maximum daily dose: 120 mg/day.
IV: 30 mg as a single dose or 30 mg every 6 hours; maximum daily dose: 120 mg/day.
Oral: Initial: 20 mg, then 10 mg every 4 to 6 hours; maximum daily dose: 40 mg/day.
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or
avoidance. Consult drug interactions database for more information.
Dosing: Kidney Impairment: Pediatric

There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments are
recommended for adult patients. The specific degree of renal impairment where use is permitted is not defined in the product labeling;
however, use is contraindicated in patients with advanced renal impairment or those at risk for renal failure due to volume depletion;
some experts have suggested the following:
Infants, Children, and Adolescents:
Aronoff 2007 recommendations: Note: Renally adjusted dose recommendations are based on doses of IV, IM: 0.25 to 1
mg/kg/dose every 6 hours (Ref).
GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.
GFR 10 to 29 mL/minute/1.73 m2: Administer 50% of dose.
GFR <10 mL/minute/1.73 m2: Administer 25% to 50% of dose.
Intermittent hemodialysis: Avoid use.
Peritoneal dialysis: Avoid use.

KDIGO guidelines provide the following recommendations for NSAIDs (Ref):
eGFR 30 to <60 mL/minute/1.73 m2: Temporarily discontinue in patients with intercurrent disease that increases risk of
acute kidney injury.
eGFR <30 mL/minute/1.73 m2: Avoid use.
Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. Use with caution, may cause elevation of liver enzymes;
discontinue if clinical signs and symptoms of liver disease develop.
Dosing: Older Adult

Avoid use (Ref).
Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] =
Discontinued product
Kit, Injection, as tromethamine:
ReadySharp Ketorolac: 15 mg/mL [DSC] [contains alcohol, usp]
Solution, Injection, as tromethamine:
Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)
Solution, Injection, as tromethamine [preservative free]:
Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)
Solution, Intramuscular, as tromethamine:
Generic: 60 mg/2 mL (2 mL)
Solution, Intramuscular, as tromethamine [preservative free]:
Generic: 60 mg/2 mL (2 mL)
Tablet, Oral, as tromethamine:
Generic: 10 mg
Generic Equivalent Available: US

May be product dependent
Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intramuscular:
Toradol: 10 mg/mL (1 mL) [contains alcohol, usp]
Solution, Intramuscular, as tromethamine:
Generic: 30 mg/mL (1 mL, 10 mL)
Tablet, Oral, as tromethamine:
Toradol: 10 mg
Generic: 10 mg
Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf, must be dispensed with this medication.
Administration: Adult
Oral: May administer with food to reduce GI upset.
IM: Administer slowly and deeply into the muscle.
IV: Administer IV bolus over a minimum of 15 seconds.
Administration: Pediatric
Oral: May administer with food or milk to decrease GI upset.
Parenteral:
IM: Administer slowly and deeply into muscle; 60 mg per 2 mL vial is for IM use only.
IV bolus: Administer undiluted over at least 15 seconds; in children, ketorolac has been infused over 1 to 5 minutes (Ref).
Use: Labeled Indications

Pain management, acute: Short-term (≤5 days) management of acute pain.
Use: Off-Label: Adult
Migraine, severe, acute treatment
Medication Safety Issues

Sound-alike/look-alike issues:
Ketorolac may be confused with Ketalar, methadone
Toradol may be confused with Foradil, Inderal, TEGretol, traMADol, tromethamine
Older Adult: High-Risk Medication:
Beers Criteria: Ketorolac is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65
years and older (independent of diagnosis or condition) due to an increased risk of GI bleeding, peptic ulcer disease, and acute
kidney injury (Beers Criteria [AGS 2019]).
Pharmacy Quality Alliance (PQA): Ketorolac is identified as a high-risk medication in patients 65 years and older on the PQA’s Use
of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and
Medicaid Services (CMS) for Medicare plans (PQA 2017).
International issues:
Toradol [Canada and multiple international markets] may be confused with Theradol brand name for tramadol [Netherlands]
Adverse Reactions
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Some reactions listed
are based on reports for other agents in this same pharmacologic class and may not be specifically reported for ketorolac.
>10%:
Gastrointestinal: Abdominal pain, dyspepsia, nausea
Hepatic: Increased liver enzymes (≤15%)
Nervous system: Headache
1% to 10%:
Cardiovascular: Edema, hypertension
Dermatologic: Diaphoresis, pruritus, skin rash
Gastrointestinal: Constipation, diarrhea, flatulence, gastrointestinal fullness, gastrointestinal hemorrhage (dose dependent,
increased incidence seen in age ≥65 years, can be severe), gastrointestinal perforation, gastrointestinal ulcer, heartburn,
stomatitis, vomiting
Hematologic & oncologic: Anemia, prolonged bleeding time, purpuric disease
Local: Pain at injection site (IM, IV)
Nervous system: Dizziness, drowsiness
Otic: Tinnitus
Renal: Renal function abnormality
<1%:
Cardiovascular: Cardiac failure, palpitations, syncope, tachycardia
Dermatologic: Alopecia, ecchymoses, pallor, skin photosensitivity, urticaria
Endocrine & metabolic: Increased thirst, weight changes
Gastrointestinal: Anorexia, dysgeusia, eructation, esophagitis, gastritis, glossitis, hematemesis, increased appetite, melena,
xerostomia
Genitourinary: Cystitis, dysuria, exacerbation of urinary frequency, hematuria, infertility, oliguria, proteinuria, urinary retention
Hematologic & oncologic: Eosinophilia, leukopenia, rectal hemorrhage, thrombocytopenia
Hepatic: Hepatitis, jaundice
Infection: Infection, sepsis
Nervous system: Abnormal dreams, abnormality in thinking, anxiety, confusion, depression, euphoria, extrapyramidal reaction,
hallucination, insomnia, lack of concentration, malaise, nervousness, paresthesia, stupor, vertigo
Neuromuscular & skeletal: Asthenia, hyperkinetic muscle activity, tremor
Ophthalmic: Blurred vision, visual disturbance
Otic: Hearing loss
Renal: Interstitial nephritis, polyuria, renal failure syndrome
Respiratory: Asthma, cough, dyspnea, epistaxis, pulmonary edema, rhinitis
Miscellaneous: Fever
Frequency not defined:
Cardiovascular: Cerebrovascular accident, coronary thrombosis
Gastrointestinal: Peptic ulcer
Postmarketing:
Cardiovascular: Acute myocardial infarction, bradycardia, cardiac arrhythmia, chest pain, flushing, hypotension, vasculitis
Dermatologic: Bullous skin disease, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal
necrolysis
Endocrine & metabolic: Hyperglycemia, hyperkalemia, hyponatremia
Gastrointestinal: Acute pancreatitis, aphthous stomatitis, exacerbation of Crohn’s disease, exacerbation of ulcerative colitis
Genitourinary: Azotemia, nephrotic syndrome
Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, hemolytic-uremic syndrome, lymphadenopathy,

pancytopenia, postoperative hematoma, postoperative wound bleeding
Hepatic: Hepatic failure, hepatotoxicity (idiosyncratic) (Chalasani 2014)
Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, nonimmune anaphylaxis, tongue edema
Immunologic: Drug rash with eosinophilia and systemic symptoms
Nervous system: Aseptic meningitis, coma, flank pain, psychosis, seizure
Neuromuscular & skeletal: Myalgia
Ophthalmic: Conjunctivitis
Renal: Acute kidney injury
Respiratory: Bronchospasm, laryngeal edema, pneumonia, respiratory depression
Contraindications
Hypersensitivity to ketorolac, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or any component of the formulation;
active or history of peptic ulcer disease; recent or history of GI bleeding or perforation; history of asthma, urticaria, or allergic-type
reactions after taking aspirin or other NSAIDs; advanced renal disease or patients at risk for renal failure due to volume depletion;
prophylactic analgesic before any major surgery; suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis,
incomplete hemostasis, or high risk of bleeding; concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline; epidural
or intrathecal administration (injection only); use in the setting of coronary artery bypass graft surgery; labor and delivery.
Canadian labeling: Additional contraindications (not in US labeling): Intraoperative use; coagulation disorders; active GI bleeding;
postoperative patients with high-bleeding risk; severe uncontrolled heart failure; inflammatory bowel disease; severe hepatic
impairment or active hepatic disease; moderate to severe renal impairment (serum creatinine >442 micromol/L and/or creatinine
clearance <30 mL/minute) or deteriorating renal disease; known hyperkalemia; third trimester of pregnancy; breast-feeding; use in
children and adolescents <18 years of age
Warnings/Precautions
Concerns related to adverse effects:
• Bleeding and hematologic effects: [US Boxed Warning]: Inhibits platelet function; contraindicated in patients with
cerebrovascular bleeding (suspected or confirmed), hemorrhagic diathesis, incomplete hemostasis and patients at high
risk for bleeding. Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation
disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term
nonsteroidal anti-inflammatory drug (NSAID) therapy should be monitored for anemia. Rarely, NSAID use has been associated
with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).
• Cardiovascular events:[US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse
cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase
with duration of use. Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors
for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early
during treatment) was higher in patients with known cardiovascular disease or risk factors and in those receiving higher doses.
New onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors,
thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in
patients with hypertension. May cause sodium and fluid retention, use with caution in patients with edema. Avoid use in heart
failure (FDA 2015). Avoid use in patients with a recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use
the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of
cardiovascular events; alternate therapies should be considered for patients at high risk.
• CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental
abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or
driving).
• Drug reaction with eosinophilia and systemic symptoms: Potentially serious, sometimes fatal, drug reaction with eosinophilia
and systemic symptoms (DRESS), also known as multiorgan hypersensitivity reactions, has been reported with NSAIDs. Monitor
for signs and symptoms (eg, fever, rash, lymphadenopathy, eosinophilia) in association with other organ system involvement
(eg, hepatitis, nephritis, hematological abnormalities, myocarditis, myositis). Early symptoms of hypersensitivity reaction (eg,
lymphadenopathy, fever) may occur without rash; discontinue therapy and further evaluate if DRESS is suspected.
• GI events: [US Boxed Warning]: Ketorolac can cause peptic ulcers, GI bleeding, and/or perforation of the stomach or
intestines, which can be fatal. These events can occur at any time during use and without warning symptoms.
Therefore, ketorolac is contraindicated in patients with active peptic ulcer disease, recent GI bleeding or perforation,
and a history of peptic ulcer disease or GI bleeding. Elderly patients and patients with a prior history of peptic ulcer
disease and/or GI bleeding are at greater risk for serious GI events. Avoid use in patients with active GI bleeding. In patients
with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis
(Strate 2016). Use caution with a history of GI ulcers, inflammatory bowel disease, concurrent therapy known to increase the risk
of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic
disease, coagulopathy, smoking, use of alcohol, or in the elderly or debilitated patients. Use the lowest effective dose for the
shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies
should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of GI
complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended
(ACC/ACG/AHA [Bhatt 2008]).
• Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare
(sometimes fatal) severe hepatic reactions (eg, jaundice, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred
with NSAID use; discontinue immediately if signs or symptoms of hepatic disease develop or if systemic manifestations occur.
• Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in patients ≥65 years of age, in patients with
diabetes or renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors).
Monitor potassium closely.
• Hypersensitivity reactions: [US Boxed Warning]: Ketorolac injection is contraindicated in patients with prior
hypersensitivity reaction to aspirin or NSAIDs. Even in patients without prior exposure, hypersensitivity including
bronchospasm and anaphylactic shock, may occur; patients with "aspirin triad" (bronchial asthma, aspirin intolerance, rhinitis)
may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or
aspirin therapy.
• Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may
result from NSAID use, reducing renal blood flow, which may cause renal decompensation (usually reversible). Patients with
impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors,
and ≥65 years of age are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function
closely. Acute renal failure, interstitial nephritis, and nephrotic syndrome have been reported with ketorolac use; papillary
necrosis and renal injury have been reported with long-term use of NSAIDs.
• Skin reactions: NSAIDs may cause potentially fatal serious skin adverse events including exfoliative dermatitis, Stevens-Johnson
syndrome, and toxic epidermal necrolysis; may occur without warning; discontinue use at first sign of skin rash (or any other
hypersensitivity).
Disease-related concerns:
• Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE)
and mixed connective tissue disorders.
• Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use
caution in patients with other forms of asthma.
• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of
anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2013). Short-term use of celecoxib or IV ketorolac are
recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016; Horsley 2019; Thorell
2016).
• Coronary artery bypass graft surgery/major surgery: [US Boxed Warning]: Use is contraindicated as prophylactic analgesic
before any major surgery and is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Risk of MI
and stroke may be increased with use following CABG surgery. Wound bleeding and postoperative hematomas have been
associated with ketorolac use in the perioperative setting.
• Hepatic impairment: Use with caution in patients with hepatic impairment or a history of hepatic disease; patients with
advanced hepatic disease are at an increased risk of GI bleeding and kidney failure with NSAIDs (AASLD [Biggins 2021]; AASLD
[Runyon 2013]).
• Renal impairment: [US Boxed Warning]: Ketorolac is contraindicated in patients with advanced renal impairment and in
patients at risk for renal failure due to volume depletion. Use with caution in patients with renal impairment or history of
kidney disease. Dosage adjustment is required in patients with moderate elevation in serum creatinine.
Concurrent drug therapy issues:
• Aspirin/other NSAIDs: [US Boxed Warning]: Concurrent use of ketorolac with aspirin or other NSAIDs is contraindicated
due to the increased risk of adverse reactions.
Special populations:
• Older adult: [US Boxed Warning]: Dosage adjustment is required for patients ≥65 years of age. Patients ≥65 years of age
are at greater risk for serious GI, cardiovascular, and/or renal adverse events; use with caution. Ketorolac is identified in the
Beers Criteria as a potentially inappropriate medication to be avoided in patients ≥65 years of age (independent of diagnosis or
condition) due to an increased risk of GI bleeding, peptic ulcer disease, and acute kidney injury (Beers Criteria [AGS 2019]).
• Labor and delivery: [US Boxed Warning]: The use of ketorolac in labor and delivery is contraindicated because it may
adversely affect fetal circulation and inhibit uterine contractions.
• Low body weight: [US Boxed Warning]: Dosage adjustment is required for patients weighing <50 kg (<110 pounds).
• Pediatric: [US Boxed Warning]: Ketorolac is not indicated for use in pediatric patients.
Dosage form specific issues:
• Oral: [US Boxed Warning]: Oral therapy is only indicated for use as continuation treatment, following parenteral
ketorolac and is not indicated for minor or chronic painful conditions.
• Oral/injection: [US Boxed Warning]: Systemic ketorolac is indicated for short-term (≤5 days) use in adults for treatment
of moderately severe acute pain requiring opioid-level analgesia. The combined therapy duration (oral and parenteral)
should not exceed 5 days due to the increased risk of serious adverse events.The recommended total daily dose of
ketorolac tablets (maximum 40 mg) is significantly lower than for ketorolac injection (maximum 120 mg).
• Injection: [US Boxed Warning]: Ketorolac injection is contraindicated for epidural or intrathecal administration
(formulation contains alcohol).
Other warnings/precautions:
• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.
Warnings: Additional Pediatric Considerations

In neonates, bleeding events have been reported; in a retrospective analysis of 57 postsurgical neonates and infants (age range: 0 to 3
months), 17.2% of patients experienced a bleeding event, most were PNA <21 days and those with PNA <14 days had a significantly
higher risk than older neonates (Aldrink 2011). Acute kidney injury (AKI) has been observed in pediatric patients; with ketorolac use
following cardiothoracic surgery, an increased risk of AKI was observed in neonates and infants who underwent a bidirectional Glenn
procedure and were receiving concomitant aspirin therapy (Moffett 2013).
Metabolism/Transport Effects
Substrate of OAT1/3
Drug Interactions
(For additional information: Launch drug interactions program)
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4
Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management
recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic
Acid Derivatives. Risk C: Monitor therapy
Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib. Management: Do not use
antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this
combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less). Risk X: Avoid combination
Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination
Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents
with Antiplatelet Properties. Risk C: Monitor therapy
Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding
may be increased with this combination. Risk C: Monitor therapy
Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-
Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Risk C: Monitor therapy
Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature
infants. Risk C: Monitor therapy
Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic).
Risk X: Avoid combination
Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk
C: Monitor therapy
Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the
combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the
therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease
glomerular filtration and renal function. Risk C: Monitor therapy
Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.
Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may
diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy
Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy
Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the
risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before
any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for
signs and symptoms of bleeding. Risk D: Consider therapy modification
Aspirin: Ketorolac (Systemic) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with
use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin. Risk X: Avoid combination
Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid
concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If
concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification
Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid
concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms
of bleeding. Risk D: Consider therapy modification
Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. Risk C: Monitor
therapy
Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy
Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate
Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. Risk C:
Monitor therapy
Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for
bleeding may be increased. Risk C: Monitor therapy
Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic).
Specifically, the risk of injection site bruising and or bleeding may be increased. Risk C: Monitor therapy
Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Risk C:
Monitor therapy
CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic).
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE
(Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to
nonsteroidal anti-inflammatory agents (NSAIDs). Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine
concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs. Risk D: Consider therapy
modification
Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran
Etexilate. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be
done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined,
monitor patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification
Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI
ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy
Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk
for bleeding or bruising in the treatment area may be increased. Risk C: Monitor therapy
Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. Risk C: Monitor
therapy
Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. Risk C: Monitor therapy
Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor
therapy
Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically,
the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients
before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra
closely for signs and symptoms of bleeding. Risk D: Consider therapy modification
Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue
nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is
unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification
Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue
antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely
for signs and symptoms of bleeding. Risk D: Consider therapy modification
Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-
Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. Risk C: Monitor therapy
Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of
fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities. Risk D: Consider
therapy modification
Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin. Management: Decrease the dose
of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required. Risk D: Consider therapy modification
Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of
heparin or agents with antiplatelet properties if coadministration is required. Risk D: Consider therapy modification
Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents
with Antiplatelet Properties. Bleeding may occur. Risk C: Monitor therapy
Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of
Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Risk C: Monitor therapy
HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. Risk C: Monitor
therapy
Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both
agents may contribute to impaired platelet function and an increased risk of bleeding. Risk C: Monitor therapy
Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination
Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Risk C: Monitor therapy
Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. Management: Consider reducing
the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose
increased, or decreased effects if a NSAID is discontinued/dose decreased. Risk D: Consider therapy modification
Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may
enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or
decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or
cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended. Risk D: Consider therapy modification
Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination
MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. Risk C: Monitor therapy
Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. Management: Avoid
coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use
caution if coadministering lower dose methotrexate and NSAIDs. Risk D: Consider therapy modification
Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). Risk C: Monitor
therapy
Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. Risk X: Avoid combination
Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C:
Monitor therapy
Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor
therapy
Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy
Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Systemic) may enhance the adverse/toxic effect of Neuromuscular-
Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C:
Monitor therapy
Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Risk C: Monitor therapy
Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Ketorolac (Systemic). Risk X: Avoid combination
Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.
Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-
inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits
outweigh the risks and monitor for increased NSAID toxicities. Risk D: Consider therapy modification
Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of
serious bleeding-related events may be increased. Risk C: Monitor therapy
Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for
bleeding-related events may be increased. Risk C: Monitor therapy
Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of
bleeding may be increased by concurrent use of these agents. Risk C: Monitor therapy
Pentoxifylline: Ketorolac (Systemic) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be
increased with this combination. Risk X: Avoid combination
Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination
Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy
Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. Risk C: Monitor
therapy
Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing
Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C:
Monitor therapy
PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically,
NSAIDS may decrease the renal excretion of pralatrexate. Management: Avoid coadministration of pralatrexate with nonsteroidal
anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or
toxicity. Risk D: Consider therapy modification
Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Risk C: Monitor therapy
Probenecid: May increase the serum concentration of Ketorolac (Systemic). Risk X: Avoid combination
Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins
(Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Risk
C: Monitor therapy
Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of
Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. Risk C: Monitor therapy
Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban.
Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all
patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor
patients extra closely for signs and symptoms of bleeding. Risk D: Consider therapy modification
Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased
risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may
diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-
Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer
ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin. Risk
D: Consider therapy modification
Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
(Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin
Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished
antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk. Risk D: Consider therapy modification
Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
(Nonselective). Risk C: Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider
discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D:
Consider therapy modification
Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute
phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment
with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain
adequate hydration and monitor renal function closely. Risk D: Consider therapy modification
Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). Risk C:
Monitor therapy
Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Risk X: Avoid combination
Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.
Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID
given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk. Risk D: Consider therapy
modification
Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination
Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Risk C: Monitor therapy
Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal
Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy
Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. Risk C:
Monitor therapy
Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of
hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory
Agents. Risk C: Monitor therapy
Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of
major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic
Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy
Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. Risk X: Avoid combination
Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. Risk C: Monitor therapy
Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy
Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of
Vitamin K Antagonists. Management: Consider alternatives to this combination when possible. If the combination must be used,
monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising. Risk D: Consider
therapy modification
Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy
Food Interactions
High-fat meals may delay time to peak (by ~1 hour) and decrease peak concentrations. Management: Administer tablet with food or milk
to decrease gastrointestinal distress.
Reproductive Considerations
Nonsteroidal anti-inflammatory drugs may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is
reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those
undergoing investigation of fertility.
Pregnancy Considerations
Ketorolac crosses the placenta (Walker 1988).
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage
due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).
Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013).
Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn,
oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage, have been observed in the
fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction
leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged
maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition,
nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).
Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks'
gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if
treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause
premature closure of the ductus arteriosus, prescribing information for ketorolac specifically states use should be avoided starting at 30
weeks' gestation
Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of ketorolac may be altered. Ketorolac has S and R
enantiomers; pharmacologic activity is associated with S-ketorolac enantiomer. The clearance of S-ketorolac was found to increase at
delivery compared to postpartum values; the peak serum concentration was decreased (Kulo 2017; Välitalo 2017).
[US Boxed Warning]: The use of ketorolac in labor and delivery is contraindicated because it may adversely affect fetal
circulation and inhibit uterine contractions. The risk of uterine hemorrhage may be increased. NSAIDs may be used as part of
multimodal pain management following cesarean delivery (ACOG 2019).
Breastfeeding Considerations
Ketorolac is present in breast milk (Wischnik 1989).
The relative infant dose (RID) of ketorolac is 0.21% when calculated using the highest breast milk concentration located and
compared to a weight-adjusted maternal dose of 40 mg/day.
In general, breastfeeding is considered acceptable when the RID is <10% (Anderson 2016; Ito 2000).
The RID of ketorolac was calculated using a milk concentration of 7.9 ng/mL providing an estimated infant dose via breast milk of
1.185 mcg/kg/day. This milk concentration was obtained following maternal administration of oral ketorolac 10 mg 4 times a day for
2 days in 10 women 2 to 6 days postpartum (Wischnik 1989).
Information related to breastfeeding is available from 3 studies that evaluated use of ketorolac as part of a multimodal protocol for
pain following cesarean delivery. In 1 study, women were given a single dose of ketorolac. There were no differences observed
between neonates exposed to the protocol containing ketorolac compared to routine standard care without ketorolac in relation to
breastfeeding, neonatal growth, sedation and respiratory depression (Hadley 2019). In a second study, ketorolac was used as
needed or as a scheduled dose every 6 hours for 24 hours. More mothers who received the scheduled doses exclusively breastfed
their newborns; the duration of breastfeeding was also increased (Teigen 2020). In a third study, the maternal dose of ketorolac (15
or 30 mg) was not found to influence the incidence of breastfeeding when used for up to 24 hours postpartum (Yurashevich 2020).
Nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred for breastfeeding patients who
require pain control peripartum or for surgery outside of the postpartum period (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]).
The manufacturer recommends that caution be used if administered to patients who are breastfeeding. Maternal use of NSAIDs
should be avoided if the breastfeeding infant has platelet dysfunction, thrombocytopenia, or a ductal-dependent cardiac lesion
(ABM [Martin 2018]; ABM [Reece-Stremtan 2017]; Bloor 2013). Agents other than ketorolac are preferred in breastfeeding patients at
risk of hemorrhage (ABM [Reece-Stremtan 2017]),
Dietary Considerations
Administer tablet with food or milk to decrease gastrointestinal distress.
Monitoring Parameters
Monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor
renal function (serum creatinine, BUN, urine output); CBC and platelets, liver function tests; chemistry profile; blood pressure; observe
for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation
Reference Range
Serum concentration: Therapeutic: 0.3 to 5 mcg/mL; Toxic: >5 mcg/mL
Mechanism of Action
Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors;
has antipyretic, analgesic, and anti-inflammatory properties
Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include
inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory
cytokine levels.
Pharmacokinetics
Onset of action: Analgesic: ~30 minutes.
Peak effect: Analgesic: ~2 to 3 hours.
Duration: Analgesic: 4 to 6 hours.
Absorption: Oral: Well absorbed (100%), administration after a high-fat meal decreased peak and delayed time to peak
concentrations by ~1 hour; IM: Rapid and complete.
Distribution: Poor penetration into cerebrospinal fluid.
Infants: Vdss: ~0.2 L/kg (McLay 2018).
Children and Adolescents <16 years: Vdss: 0.18 L/kg (McLay 2018).
Adults: Vd beta: Oral, IM: 0.17 ± 0.04 L/kg; IV: 0.21 ± 0.04 L/kg.
Protein binding: 99%.

Metabolism: Hepatic; undergoes hydroxylation and glucuronide conjugation.
Bioavailability: Oral, IM: 100%.
Half-life elimination:
Infants ≥6 months: S-enantiomer: 0.83 ± 0.7 hours; R-enantiomer: 4 ± 0.8 hours (Lynn 2007).
Children and Adolescents ≤16 years: 3 ± 1.1 hours (Dsida 2002).
Adults:
Mean: ~5 hours; Range: 2 to 9 hours [S-enantiomer ~2.5 hours (biologically active); R-enantiomer ~5 hours]; Prolonged 30%
to 50% in elderly.
With renal impairment: Scr 1.9 to 5 mg/dL: Mean: ~11 hours; Range: 4 to 19 hours.
Renal dialysis patients: Mean: ~14 hours; Range: 8 to 40 hours.
Time to peak, serum: Oral: ~45 minutes; IM: ~30 to 45 minutes; IV: 1 to 3 minutes.
Excretion: Urine (92%, ~60% as unchanged drug); feces ~6%.
Pharmacokinetics: Additional Considerations
Altered kidney function: Clearance is reduced and half-life is increased in renal impairment. AUC is increased by ~100% and volume
of distribution increases.
Pediatric: Vd and clearance are higher in pediatric patients compared to adults.
Older adult: Half-life is longer in patients ≥65 years of age.
Pricing: US
Solution (Ketorolac Tromethamine Injection)
15 mg/mL (per mL): $0.95 - $4.50
30 mg/mL (per mL): $1.04 - $7.61
Solution (Ketorolac Tromethamine Intramuscular)
60 mg/2 mL (per mL): $0.54 - $3.75
Tablets (Ketorolac Tromethamine Oral)
10 mg (per each): $2.16 - $2.27
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided
when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine
the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate
any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.
Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to
accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or
consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Brand Names: International

Acuvail (BH);
Adolor (EG);
Altrom (EC);
Analac (TW, VN);
Arolak (BD);
Arvolac (PH);
Bedoral (ZA);
Dilox (CL);
Dolac (BF, BJ, CI, ET, GH, GM, GN,
ID, KE, LR, MA, ML, MR, MU, MW, NE, NG, RU, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);
Dolorex (PE);
Dolorex Gel (PE);
Dolten (AR, PY);
Eleadol
(UY);
Erphapain (ID);
Eurolac (PH);
Fam (EG);
Farpain (ID);
Inco (TW);
Kelac (IN);
Kenalgesic (CO);
Keromin (KR);
Ketanov (IN, LV, PH, RO);
Keto (HK, ID, MY, PH, SG);
Ketobet (PH);
Ketogesic (VN);
Ketolac (LB, TH);
Ketolong (UA);
Ketomed (PH);
Ketoracin (KR);
Ketoral (AU);
Ketorol (LK, RO);
Ketron (CO);
Kine (PE);
Korac (BD);
Kortezor (PH);
Minolac (BD);
Ni Song (CN);
Nomadol (EC);
Notolac (EC, VE);
Ocudol (VE);
Oradol (PH);
Painoff (TW);
Poenkerat (PY);
Remopain (ID);
Rolac (LK);
Rolesen (EC);
Scelto (ID);
Supradol (PA, SV);
Tabel (KR);
Taradyl (BE);
Teromac (PH);
Tora-Dol (CH);
Toradol (AE, AU, BH, CY, DK, EC, ES, FI, HK, ID, IQ, IR, IS, IT, JO, KW, LB, LY, NO, OM, PH, PK, QA, SA, SE, SY, YE);
Toramed (PH);
Toramine (ID);
Torpain (ID);
Tral (PH);
Trolac (ID, KR);
Winop (BD);
Xevolac (MY, PH, TH);
Zerodol (BR)
For country abbreviations used in Lexicomp ( show table)
Use of UpToDate is subject to the Terms of Use.
REFERENCES
1. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate
medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767 [PubMed 30693946]
2. Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and
thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619-2633.
doi:10.1161/CIR.0b013e318202f70 [PubMed 21060077]
3. Aldrink JH, Ma M, Wang W, Caniano DA, Wispe J, Puthoff T. Safety of ketorolac in surgical neonates and infants 0 to 3 months old. J Pediatr Surg. 2011;46(6):1081-
1085
4. American Academy of Pediatrics Committee on Fetus and Newborn; American Academy of Pediatrics Section on Surgery; Canadian Paediatric Society Fetus and
Newborn Committee, et al, "Prevention and Management of Pain in the Neonate: An Update," Pediatrics, 2006, 118(5):2231-41. [PubMed 17079598]
5. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. Obstet Gynecol. 2019;133(3):e208-
e225. [PubMed 30801474]
6. American College of Surgeons (ACS). ACS Trauma Quality Programs best practices guidelines for acute pain management in trauma patients.
https://www.facs.org/-/media/files/quality-programs/trauma/tqip/acute_pain_guidelines.ashx. Published November 2020. Accessed August 30, 2021.
7. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
8. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of
Physicians; 2007.
9. Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before
and during pregnancy. Curr Opin Rheumatol. 2014;26(3):334-340. [PubMed 24663106]
10. Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and
experimental studies. World J Surg. 2014;38(9):2247-2257. doi: 10.1007/s00268-014-2531-1. [PubMed 24682313]
11. Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008
expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation
Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-1909. doi:10.1161/CIRCULATIONAHA.108.191087 [PubMed 18836135]
12. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021
practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884 [PubMed 33942342]
13. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063-1075. [PubMed
23558845]
14. Buck ML, “Clinical Experience With Ketorolac in Children,” Ann Pharmacother, 1994, 28(9):1009-13. [PubMed 7803871]
15. Buckley MM and Brogden RN, "Ketorolac. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential," Drugs, 1990, 39(1):86-109.
[PubMed 2178916]
16. Burd RS and Tobias JD, "Ketorolac for Pain Management After Abdominal Surgical Procedures in Infants," South Med J, 2002, 95(3):331-3. [PubMed 11902701]
17. Capone ML, Sciulli MG, Tacconelli S, et al, “Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,” J Am Coll Cardiol, 2005,
45(8):1295-301. [PubMed 15837265]
18. Carpuject (ketorolac tromethamine) [prescribing information]. Lake Forest, IL: Hospira, Inc; March 2021.
19. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol.
2014;109(7):950-966. [PubMed 24935270]
20. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American
Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and
Administrative Council [published correction appears in J Pain. 2016;17(4):508-510]. J Pain. 2016;17(2):131-157. doi: 10.1016/j.jpain.2015.12.008. [PubMed
26827847]
21. Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory
drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2 [PubMed 31273431]
22. Dawkins TN, Barclay CA, Gardiner RL, et al, "Safety of Intravenous Use of Ketorolac in Infants Following Cardiothoracic Surgery," Cardiol Young, 2009, 19(1):105-8.
[PubMed 19134246]
23. Dsida RM, Wheeler M, Birmingham PK, et al, "Age-Stratified Pharmacokinetics of Ketorolac Tromethamine in Pediatric Surgical Patients," Anesth Analg, 2002,
94(2):266-70. [PubMed 11812682]
24. Etches RC, Warriner CB, Badner N, et al. Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee
arthroplasty. Anesth Analg. 1995;81(6):1175-1180. [PubMed 7486100]
25. Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. Drug Saf. 1997;16(5):309-329. [PubMed 9187531]
26. Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;82(11):976-983.
doi:10.1212/WNL.0000000000000223 [PubMed 24523483]
27. Friedrichsdorf SJ, Goubert L. Pediatric pain treatment and prevention for hospitalized children. Pain Rep. 2019;5(1):e804. doi:10.1097/PR9.0000000000000804
[PubMed 32072099]
28. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
29. Golightly LK, Teitelbaum I, Kiser TH, et al, eds. Renal Pharmacotherapy. New York, NY: Springer Science; 2013
30. Gupta A, Daggett C, Drant S, et al, "Prospective Randomized Trial of Ketorolac After Congenital Heart Surgery," J Cardiothorac Vasc Anesth, 2004, 18(4):454-7.
[PubMed 15365927]
31. Gupta A, Daggett C, Ludwick J, et al, "Ketorolac After Congenital Heart Surgery: Does It Increase the Risk of Significant Bleeding Complications?" Paediatr Anaesth,
2005, 15(2):139-42. [PubMed 15675931]
32. Hadley EE, Monsivais L, Pacheco L, et al. Multimodal pain management for cesarean delivery: a double-blinded, placebo-controlled, randomized clinical trial. Am J
Perinatol. 2019;36(11):1097-1105. doi:10.1055/s-0039-1681096 [PubMed 30822800]
33. Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass.
Obes Surg. 2019;29(2):394-400. doi: 10.1007/s11695-018-3526-z. [PubMed 30317488]
34. Howard ML, Isaacs AN, Nisly SA. Continuous infusion nonsteroidal anti-inflammatory drugs for perioperative pain management. J Pharm Pract. 2018;31(1):66-81.
[PubMed 27580638]
35. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
36. Ketorolac tromethamine injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; May 2021.
37. Ketorolac tromethamine injection [prescribing information]. Lake Forest, IL: Hospira Inc; November 2021.
38. Ketorolac tromethamine injection [product monograph]. Mississauga, Ontario, Canada: Juno Pharmaceuticals Corp; September 2020.
39. Ketorolac tromethamine injection [prescribing information]. Pine Brook, NJ: Alvogen, Inc; December 2020.
40. Ketorolac tromethamine oral [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; October 2020.
41. Ketorolac tromethamine tablet [prescribing information]. Mason, OH: Burel Pharmaceuticals; December 2021.
42. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney
disease. Kidney Int. 2013;3(suppl):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.
43. Kulo A, Smits A, Maleškić S, Van de Velde M, Van Calsteren K, De Hoon J, Verbesselt R, Deprest J, Allegaert K. Enantiomer-specific ketorolac pharmacokinetics in young
women, including pregnancy and postpartum period. Bosn J Basic Med Sci. 2017;17(1):54-60. doi:10.17305/bjbms.2016.1515 [PubMed 27968707]
44. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42(2):217-228. doi:10.1016/s0272-
6386(03)00645-0 [PubMed 12900801]
45. Lynn AM, Bradford H, Kantor ED, et al, "Postoperative Ketorolac Tromethamine Use in Infants Aged 6-18 Months: The Effect on Morphine Usage, Safety Assessment,
and Stereo-Specific Pharmacokinetics," Anesth Analg, 2007, 104(5):1040-51. [PubMed 17456651]
46. Mariano ER. Management of acute perioperative pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 14, 2020.
47. Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. Breastfeed Med.
2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm [PubMed 29595994]
48. McLay JS, Engelhardt T, Mohammed BS, et al. The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. Paediatr
Anaesth. 2018;28(2):80-86. doi:10.1111/pan.13302 [PubMed 29266539]
49. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery
patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery.
Surg Obes Relat Dis. 2013;9(2):159-191. doi: 10.1016/j.soard.2012.12.010. [PubMed 23537696]
50. Micu MC, Micu R, Ostensen M. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with
inflammatory arthropathies. Arthritis Care Res (Hoboken). 2011;63(9):1334-1338. doi:10.1002/acr.20510 [PubMed 21618455]
51. Moffett BS, Cabrera A. Ketorolac-associated renal morbidity: risk factors in cardiac surgical infants. Cardiol Young. 2013;23(5):752-754. [PubMed 23088994]
52. Moffett BS, Wann TI, Carberry KE, et al, "Safety of Ketorolac in Neonates and Infants After Cardiac Surgery," Paediatr Anaesth, 2006, 16(4):424-8. [PubMed 16618297]
53. Penk JS, Lefaiver CA, Brady CM, Steffensen CM, Wittmayer K. Intermittent versus continuous and intermittent medications for pain and sedation after pediatric
cardiothoracic surgery; a randomized controlled trial. Crit Care Med. 2018;46(1):123-129. doi:10.1097/CCM.0000000000002771 [PubMed 29028762]
54. Pharmacy Quality Alliance. Use of high-risk medications in the elderly (2017 update) (HRM-2017). https://www.pqaalliance.org/medication-safety. Published 2017.
Accessed March 21, 2019.
55. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 7th ed. Glenview, IL: American Pain Society; 2016.
56. Ready LB, Brown CR, Stahlgren LH, et al. Evaluation of intravenous ketorolac administered by bolus or infusion for treatment of postoperative pain. A double-blind,
placebo-controlled, multicenter study. Anesthesiology. 1994;80(6):1277-1286. [PubMed 8010474]
57. Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM Clinical Protocol #15: Analgesia and anesthesia for the breastfeeding mother,
revised 2017. Breastfeed Med. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt [PubMed 29624435]
58. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due
to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi:10.1002/hep.26359 [PubMed 23463403]
59. Schwedt TJ, Garza Ivan. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 12,
2021.
60. Schwinghammer AJ, Isaacs AN, Benner RW, Freeman H, O'Sullivan JA, Nisly SA. Continuous infusion ketorolac for postoperative analgesia following unilateral total
knee arthroplasty. Ann Pharmacother. 2017;51(6):451-456. [PubMed 28478713]
61. Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol. 2016;111(4):459-474. doi:
10.1038/ajg.2016.41. [PubMed 26925883]
62. Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013;53(2):277-287.
doi:10.1111/head.12009 [PubMed 23298250]
63. Teigen NC, Sahasrabudhe N, Doulaveris G, et al. Enhanced recovery after surgery at cesarean delivery to reduce postoperative length of stay: A randomized
controlled trial. Am J Obstet Gynecol. 2020;222(4):372.e1–372.e10. [PubMed 31669738]
64. Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations.
World J Surg. 2016;40(9):2065-2083. doi: 10.1007/s00268-016-3492-3. [PubMed 26943657]
65. Toradol (ketorolac) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; April 2022.
66. Toradol IM (ketorolac) [product monograph]. Brantford, Ontario, Canada: Methapharm Inc; August 2020.
67. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs)
can cause heart attacks or strokes. 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-
aspirin-nonsteroidal-anti-inflammatory.
68. US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic.
Published October 15, 2020. Accessed October 20, 2020.
69. Välitalo PA, Kemppainen H, Kulo A, et al. Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol.
2017;83(9):1966-1975. [PubMed 28429492]
70. Walker JJ, Johnstone J, Lloyd J, et al, "Transfer of Ketorolac Tromethamine From Maternal to Foetal Blood," Eur J Clin Pharmacol, 1988, 34(5):509-11. [PubMed
3264528]
71. Watcha MF, Ramirez-Ruiz M, White PF, Jones MB, Lagueruela RG, Terkonda RP. Perioperative effects of oral ketorolac and acetaminophen in children undergoing
bilateral myringotomy. Can J Anaesth. 1992;39(7):649-654. [PubMed 1394752]
72. Wischnik A, Manth SM, Lloyd J, et al, "The Excretion of Ketorolac Tromethamine Into Breast Milk After Multiple Oral Dosing," Eur J Clin Pharmacol, 1989, 36(5):521-4.
[PubMed 2787750]
73. Yurashevich M, Pedro C, Fuller M, Habib AS. Intra-operative ketorolac 15 mg versus 30 mg for analgesia following cesarean delivery: a retrospective study. Int J
Obstet Anesth. 2020;44:116-121. doi:10.1016/j.ijoa.2020.08.009 [PubMed 32947103]
74. Based on expert opinion.
75. Refer to manufacturer labeling.

76. Refer to Canadian labeling.
Topic 9152 Version 518.0

Ketorolac (Systemic) - Drug Information - UpToDate

Uploaded by

Copyright:

Available Formats

Ketorolac (Systemic) - Drug Information - UpToDate

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ketorolac (Systemic) - Drug Information - UpToDate

Uploaded by

Copyright:

Available Formats

1/11/22, 6:59 Ketorolac (systemic): Drug information - UpToDate

Official reprint from UpToDate®

Ketorolac (systemic): Drug information

Copyright 1978-2022 Lexicomp, Inc. All rights reserved.

ALERT: US Boxed Warning

Cardiovascular thrombotic events:

Ketorolac is contraindicated in the setting of coronary artery bypass graft surgery.

Intrathecal or epidural administration:

Ketorolac is contraindicated as a prophylactic analgesic before any major surgery.

Risk during labor and delivery:

Concomitant use with nonsteroidal anti-inflammatory drugs:

Brand Names: Canada

Migraine, severe, acute treatment 

Migraine, severe, acute treatment (off-label use):

Weight ≥50 kg and <65 years of age:

IV: 30 mg once (Ref).

IM: 60 mg once (Ref).

Weight <50 kg or ≥65 years of age:

IV: 15 mg once (Ref).

IM: 30 mg once (Ref).

Pain management, acute:

Weight ≥50 kg and <65 years of age:

Weight <50 kg or ≥65 years of age:

Dosing: Kidney Impairment: Adult

Dosage adjustment recommendations:

Altered kidney function:

eGFR 10 to 50 mL/minute/1.73 m2:

Dosing: Hepatic Impairment: Adult

(For additional information see "Ketorolac (systemic): Pediatric drug information")

Pain management (acute; moderately severe):

Children ≥2 years and Adolescents ≤16 years: Limited data available:

IM: 30 mg as a single dose or 15 mg every 6 hours; maximum daily dose: 60 mg/day.

IV: 15 mg as a single dose or 15 mg every 6 hours; maximum daily dose: 60 mg/day.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents:

GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.

GFR 10 to 29 mL/minute/1.73 m2: Administer 50% of dose.

GFR <10 mL/minute/1.73 m2: Administer 25% to 50% of dose.

Intermittent hemodialysis: Avoid use.

Peritoneal dialysis: Avoid use.

KDIGO guidelines provide the following recommendations for NSAIDs (Ref):

eGFR <30 mL/minute/1.73 m2: Avoid use.

Dosing: Hepatic Impairment: Pediatric

Dosing: Older Adult

Kit, Injection, as tromethamine:

ReadySharp Ketorolac: 15 mg/mL [DSC] [contains alcohol, usp]

Solution, Injection, as tromethamine:

Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)

Solution, Injection, as tromethamine [preservative free]:

Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)

Solution, Intramuscular, as tromethamine:

Generic: 60 mg/2 mL (2 mL)

Solution, Intramuscular, as tromethamine [preservative free]:

Generic: 60 mg/2 mL (2 mL)

Tablet, Oral, as tromethamine:

Generic Equivalent Available: US

Dosage Forms: Canada

Toradol: 10 mg/mL (1 mL) [contains alcohol, usp]

Solution, Intramuscular, as tromethamine: